CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 74 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04604912
NCT04604912N/ACompleted

Multi-omics Endotyping of Food-allergic Patients For Advanced Biomarker Discovery

Luxembourg Institute of Health·observational·Posted Oct 27, 2020·Updated Mar 8, 2024

In Brief

An observational study for Allergy;Food. Completed, enrolled 74 participants across 2 sites.

Detailed Summary

Food allergy is a global burden, affecting patients, society as a whole and the economy. For most common food allergies, patients synthesize specific IgE-antibodies against harmless food proteins. Clinical phenotypes of food-allergic patients are highly diverse. Differences in medical symptoms (organs, severity, delay), threshold and cross-reactivity levels suggest variable underlying endotypes. The aim of this study is to identify phenotypic biomarkers for advanced stratification of food-allergic patients. Our study will consist of up to 50 participants (30 food-allergic, 20 tolerant), recruited in Luxembourg. Clinical samples will be collected before, during and after the event of a double-blind placebo-controlled food challenge for patients. Multi-omics analyses of blood (sera, peripheral blood mononuclear cell, basophils) and stool will allow a deeper understanding of the underlying immune mechanisms, including allergen metabolism aspects, as well as the functional gut microbiome. Deciphering these basic aspects during the present pilot study is expected to pave the way towards novel personalized medicine approaches for diagnosing and treating of food-allergic individuals. This study is a cooperation project between the Centre Hospitalier de Luxembourg (CHL), the Luxemburg Institute of Health (LIH), the University of Luxembourg and the Integrated Biobank of Luxemburg (IBBL).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAllergy;Food
CountriesLuxembourg

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedOct 27, 2020
Enrollment StartSep 1, 2017
Primary CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 5.7 years ago